Floatz logo

HUMAN INTERLEUKIN 2 (IL2, T-CELL GROWTH FACTOR, TCGF) (2-133) VARIANT (A1 DELETED, PRO65>LYS, CYS125>SER), NON-GLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI, CONJUGATED AT N6 OF K65 WITH A PEG DERIVATIVE (30KDA)

Oesophageal Squamous Cell Carcinoma

Sanofiprotein_peptidePhase 2Active
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
95/ 100

Competitive context

64 Active assets in the Oesophageal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
AstraZeneca
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Levoleucovorin
Taiho Oncology, Inc.
Phase 3BB
Cetuximab
Hummingbird Bioscience
Phase 2B

View all 50 →

Same molecule, other indications

HUMAN INTERLEUKIN 2 (IL2, T-CELL GROWTH FACTOR, TCGF) (2-133) VARIANT (A1 DELETED, PRO65>LYS, CYS125>SER), NON-GLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI, CONJUGATED AT N6 OF K65 WITH A PEG DERIVATIVE (30KDA) is also rated in:

gastric cancerDormant
C
Indicative ·
33 / 100
View asset →
hepatocellular carcinomaDormant
C
Indicative ·
33 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →